Phase 2 N=63 Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis
Multiple Sclerosis
Primary: Symbol Digit Modalities Test (SDMT) — 36.9; 46.8 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=120 A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
COVID-19
Primary: Time to Sustained Recovery Through Day 29 — 12.00; 13.00; 13.00 days — p=0.7273
N/A N=11 Adapting Behavioral Activation to Technology Platform
Depression
Primary: Patient Health Questionnaire-Adolescent (PHQ-8) — 9.60 units on a scale
Phase 2 N=140 A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea
Rosacea
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 5; 6 Participants
Phase 3 N=74 Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day
Tobacco Use Disorder
Primary: Feasibility as Indicated by Self-reported Adherence to Study Cigarettes. — 7.1; 7.3; 10.4; 13.3 Percent non-study cigarettes per day
N/A N=110 BIO|CONCEPT.Renamic Neo Study
Medical Devices
Primary: Number of Adverse Device Effects (ADE) and Device Deficiencies (DD) Per Number of Implantations and Per Number of PHD/Follow-up Cases — 0 use cases for Renamic Neo
Phase 2 N=40 Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
Neurogenic Orthostatic Hypotension
Primary: Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score — 4.61; 4.17; 3.35; 3.5 Score on a scale
Phase 2 N=22 Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Fibromyalgia
Primary: Mean (SD) Glx/Total Creatine Levels in Dorsal Anterior Cingulate Cortex (dACC): NYX-2925 20 mg and 200 mg PO QD at Week 4 and Week 6, Respectively. — 2.1670; 2.0550…
N/A N=242 A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus
Barrett Esophagus
Primary: Number of Subjects That Would Have This Procedure Again — 19; 16 Participants
N/A N=201 Using Group Commitment for Smoking Cessation
Smoking
Primary: Smoking Status at 6 Months — 57; 13 Participants
Phase 2 N=14 Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Prostatic Neoplasms · Neoplasms of Prostate · Prostate Cancer
Primary: Number of Grade 3 Adverse Events (AEs) Probably Related to the Vaccine Treatment — 1 Adverse events
N/A N=668 Prevalence of Chronic Inebriates to the Emergency Department and Suitability for Sobering House Services
Alcohol Intoxication
Primary: Intoxicated Patients Eligible for a Sobering House — 163 Participants
Phase 2 N=69 CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Clear Cell Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.91; 3.81 months — p=0.07905
Phase 2 N=156 A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs — 24; 21; 22; 6 Participants
Phase 2 N=40 The Effects of Cannabidiol on the Driving Ability of Healthy Adults
Driving Performance · Cognitive Impairment · Sedation Complication
Primary: Driving Performance - Percent of Time Spent Out of Lane — 4.41; 4.34 Percent time spent driving out of lane — p=0.9460